Skip to Content
Søk Menu

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

The combination of abemaciclib and trastuzumab improved survival rates in women with HR+, HER2+ advanced breast cancer compared to chemotherapy plus trastuzumab, with a manageable safety profile.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Consecutive Mammography Screening Is the Best Way to Reduce the Risk of Premature Death from Breast Cancer

/ Sofie Pohl
Brystkreft

Recent Updates in Breast Cancer Screening – A Norwegian Perspective

/ Kaitlyn Tsuruda / Solveig Hofvind
Brystkreft
László Tabár

Mammography Screening Is the Best Way to Reduce the Risk of a Premature Death from Breast Cancer

/ László Tabár
Brystkreft Play the Video 7:11

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

/ Sofie Pohl
ASCOGI24BrystkreftGastrointestinal kreft
Hatem Azim

Using Fertility Options May be Safe for Patients with HR-positive Breast Cancer

/ Hatem Azim
BrystkreftSABCS23 Play the Video 10:10
Terry Mamounas

The Effectiveness of Regional Nodal Radiation in Patients with Breastcancer

/ Eleftherios (Terry) P. Mamounas
BrystkreftSABCS23 Play the Video 13:26

SABCS 2023: HR-Positive Breast Cancer Patients May Safely Use Fertility Options

/ BestPractice Nordic
BrystkreftSABCS23

SABCS 2023: Younger Postmenopausal Women May Safely Skip Adjuvant Radiotherapy

/ BestPractice Nordic
BrystkreftSABCS23

SABCS 2023: Neoadjuvant Chemotherapy: May Reduce Regional Nodal Irradiation in Breast Cancer Patients

/ BestPractice Nordic
BrystkreftSABCS23
Back to top